Krystal Biotech, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Regular earnings reports show if a company is making or losing money, helping you track its financial health.
Quarterly reports provide detailed financial statements showing revenue, expenses, and assets at a specific point in time.
Patent filings protect inventions and show progress on future products that could drive company growth.
Board elections determine who leads the company's decisions; voting results show investor confidence in leadership.
Quarterly reports let you see how the company is performing and whether it is meeting its goals.
Year-end earnings show if a company met its annual goals and help you understand overall business performance.
Annual reports detail all major business activities, finances, and risks, giving you the full picture of company health.
Stocky reads Krystal Biotech, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Krystal Biotech, Inc.'s most recent tracked filing was a 8-K on 3 Aug 2026: Announces second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.